| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.05 | 0.3 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |